Jasper Therapeutics (JSPR) Tax Provisions (2020)
Jasper Therapeutics (JSPR) posted Tax Provisions of -$9962.0 for Q4 2020, down 21.27% on a QoQ basis from -$8215.0 in Q3 2020.
Powered by 
Analysis
Jasper Therapeutics (JSPR) Tax Provisions (2020) Analysis & Trends
Jasper Therapeutics has reported Tax Provisions for 1 years, with the latest figure at -$9962.0 in Q4 2020.
- On a quarterly basis, Tax Provisions changed N/A year-over-year to -$9962.0 in Q4 2020; TTM through Dec 2020 was $38451.0, a N/A change from a year earlier, with the FY2020 full-year figure at $38451.0, up 136.99% from the prior year.
- Tax Provisions was -$9962.0 for Q4 2020 at Jasper Therapeutics, down from -$8215.0 in the prior quarter.
- The five-year high for Tax Provisions was $57823.0 in Q1 2020, with the low at -$9962.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 393.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 242.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 292.00 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 230.90 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -59.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 15.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 34.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -3.96 Mn |
| 10 | Jasper Therapeutics | 20.11 Mn | 20.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | -9,962.00 |
| Sep 30, 2020 | -8,215.00 |
| Jun 30, 2020 | -1,195.00 |
| Mar 31, 2020 | 57,823.00 |